Pyrido<3,4-f>chinoxalin | 73290-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Pyrido<3,4-f>chinoxalin
• 英文别名: pyrido[3,4-f]quinoxaline；Pyrazinoisoquinoline；pyrido[3,4-f]quinoxaline
• CAS: 73290-44-5
• 化学式: C₁₁H₇N₃
• mdl: MFCD18448323
• 分子量: 181.197
• InChiKey: CCSONKKTCMHYFI-UHFFFAOYSA-N

物化性质

• 沸点：
  388.0±22.0 °C(Predicted)
• 密度：
  1.319±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-[(E)-2-pyridin-4-ylethenyl]pyrazine 以32%的产率得到
  参考文献：
  名称：

  AKIHIRO OHTA; KAZUKO HASEGAWA; KATSUYO AMANO; CIHARU MORI; AKIKO OHSAWA; +, CHEM. AND PHARM. BULL., 1979, 27, NO 11 2596-2601

  摘要：

  DOI：

文献信息

• [EN] NOVEL SPIROINDOLINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE SPIROINDOLINE
  申请人：INTERVET INT BV

  公开号：WO2013017678A1

  公开（公告）日：2013-02-07

  This invention relates to novel spiroindoline compounds of formula (I) that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to the preparation of said compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  本发明涉及一种新型螺环吲哚烷化合物，通式为(I)，通常用作药物，更具体地用作动物药物。该药物可用于治疗蠕虫感染和寄生虫病的治疗，比如由蠕虫感染引起的寄生虫病。本发明还涉及利用这些化合物制备药物和治疗方案，包括将这些化合物用于需要治疗的动物。此外，本发明还涉及所述化合物的制备。此外，本发明还涉及包含这些化合物的药物组合物和工具包。
• [EN] SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS DE PYRAZINO[2,1-A]ISOQUINOLINE POUR LE TRAITEMENT DES TROUBLES DU SNC
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016030306A1

  公开（公告）日：2016-03-03

  The present invention relates to a compound of formula (I) wherein R1/R2 are independently from each other hydrogen or halogen; L is a bond, -NH-, -C(O)NH-, -NHC(O)- or NHC(O)NH-; R is hydrogen, lower alkyl, cycloalkyl, benzyl, phenyl or a five or six membered heteroaryl group, wherein phenyl and the heteroaryl groups are optionally substituted by one or two substituents, selected from halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl or di-lower alkyl amino or R is halogen if L is a bond. or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers. The compounds of formulas (I) have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及一种化合物，其化学式为（I），其中R1/R2分别独立地为氢或卤素；L为键，-NH-，-C（O）NH-，-NHC（O）-或NHC（O）NH-；R为氢，低碳链烷基，环烷基，苄基，苯基或五元或六元杂环芳基，其中苯基和杂环芳基可以选择地被一个或两个取代基所取代，所述取代基选自卤素，低碳链烷基，低碳链烷氧基，被卤素取代的低碳链烷基，被卤素取代的低碳链烷氧基，环烷基或二低碳链氨基；如果L为键，则R为卤素。或其药学上适宜的酸盐，所有外消旋混合物，它们对应的对映体和/或光学异构体。化合物的化学式（I）对痕量胺相关受体（TAARs）有很好的亲和力，特别是对TAAR1，可用于治疗抑郁症、焦虑症、躁郁症、注意力缺陷多动障碍（ADHD）、与压力相关的疾病、精神疾病如精神分裂症、神经系统疾病如帕金森病、神经退行性疾病如阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用和代谢性疾病如进食障碍、糖尿病、糖尿病并发症、肥胖、脂质代谢异常、能量消耗和吸收异常、体温稳态异常、睡眠和昼夜节律异常以及心血管疾病。
• [EN] S PIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHI CS<br/>[FR] COMPOSÉS SPIROINDOLINES DESTINÉS À ÊTRE UTILISÉS COMME AGENTS ANTHELMINTHIQUES
  申请人：INTERVET INT BV

  公开号：WO2011095581A1

  公开（公告）日：2011-08-11

  This invention relates to spiroindoline compounds for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

  这项发明涉及用于治疗蠕虫感染和寄生虫病的螺环吲哚类化合物。这项发明还涉及利用这些化合物制备药物和治疗方法，包括将这些化合物用于需要治疗的动物的治疗。此外，这项发明还涉及包含这些化合物的药物组合物和工具包。
• Fused-polycyclic compounds
  申请人：——

  公开号：US20040204418A1

  公开（公告）日：2004-10-14

  The present invention provides a novel a condensed polycyclic compound useful as a phosphodiesterase 4 inhibitor, which is shown by the formula [I]: 1 or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

  本发明提供了一种新型的紧凑多环化合物，用作磷酸二酯酶4抑制剂，其由式(I)所示：其中R1，R2，R3，R4，R5和R6如上所述，或其药学上可接受的盐，并且还提供了含有该化合物的制药组合物。
• Condensed polycyclic compounds
  申请人：Ukita Tatsuzo

  公开号：US20070004739A1

  公开（公告）日：2007-01-04

  The present invention provides a novel a condensed polycyclic compound useful as a phosphodiesterase 4 inhibitor, which is shown by the formula [I]: or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same.

  本发明提供了一种新型的紧凑型多环化合物，可用作磷酸二酯酶4抑制剂，其由式[I]所示：或其药学上可接受的盐以及含有该化合物的制药组合物。